Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Gleevec (imatinib; Novartis) Drug Analysis 2018: An Orally Administered BCR-ABL Tyrosine Kinase Inhibitor (TKI) - ResearchAndMarkets.com

Research and Markets
Posted on: 16 Feb 18

The "Drug analysis: Gleevec" drug pipelines has been added to ResearchAndMarkets.com's offering.

Gleevec (imatinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor (TKI). The BCR-ABL fusion gene activates a number of signaling pathways that facilitate cancer cell transformation and proliferation, the inhibition of apoptosis, and adhesion and cytoskeleton abnormalities, all of which are characteristics of the disease.

The presence of this gene is a result of the Philadelphia chromosome translocation, which is found in over 90% of chronic myeloid leukemia (CML) cases.

Novartis's BCR-ABL TKI is marketed as Gleevec in the US, and Glivec outside the US for a number of different oncology indications. These include CML, acute lymphoblastic leukemia, and gastrointestinal stromal tumors.

Key Topics Covered:

List of Figures

Figure 1: Gleevec for CML - SWOT analysis

Figure 2: Drug assessment summary of Gleevec for CML

Figure 3: Drug assessment summary of Gleevec for CML

Figure 4: Gleevec - SWOT analysis in acute lymphoblastic leukemia

Figure 5: Drug assessment summary for Gleevec in acute lymphoblastic leukemia

Figure 6: Drug assessment summary for Gleevec in acute lymphoblastic leukemia

List of Tables

Table 1: Gleevec drug profile

Table 2: Gleevec pivotal trial data in CML

Table 3: Gleevec late-phase trial data in CML

Table 4: Gleevec drug profile

Table 5: Pivotal clinical trial data for Gleevec in acute lymphoblastic leukemia

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vcpd59/gleevec?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180216005294/en/

Business Wire
www.businesswire.com

Last updated on: 16/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.